Latest news
25 items- PRCENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital PartnersCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company") today announced it has closed its transaction to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited ("Charme"). As announced on November 13, 2024, the Company had entered into definitive agreements with Charme for the sale of 100% ownership in Centogene GmbH, CENTOGENE's sole operating subsidiary, certain intercompany receivables, and assumption of the Company's loan granted by Oxford Finance LLC (the "Transaction"). On December 4, 2024, the Company held an Extraordinary General Meeting ("EGM") in connection with th
- PRCENTOGENE Announces Voting Results of Extraordinary General MeetingCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's Extraordinary General Meeting. Shareholders voted in favor of all proposals, which included the approval of the previously announced envisaged sale and transfer of Centogene GmbH to Charme Capital Partners Limited, a pan-European private equity firm. At the Extraordinary General Meeting of CENTOGENE, 57.16% of the Company's issued share capital were represented. About CENTOGENE CENTOGENE's mi
- PRCENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital PartnersCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a Share Purchase Agreement ("SPA") pursuant to which its operating subsidiaries will be sold to an affiliate of Charme Capital Partners Limited ("Charme"), a pan-European private equity firm, for a cash purchase price of EUR 8,717,906.80. In connection with the transaction, Centogene GmbH will receive funding, secured by Saudi accounts receivables, from its Saudi Arabian
- PRCENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet NeurologyRostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findingsData from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data from the Company's Rostock International Parkinson's Disease (ROPAD), further supporting the association of a RAB32 gene mutation with Pa
- SECSEC Form 6-K filed by Centogene N.V.6-K - Centogene N.V. (0001757097) (Filer)
- SECSEC Form 6-K filed by Centogene N.V.6-K - Centogene N.V. (0001757097) (Filer)
- PRCENTOGENE Receives Delisting Notice From NasdaqCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE'S common stock from Nasdaq. The notice indicates that CENTOGENE (the "Company") remains noncompliant with Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum USD 15 million market value of publicly held shares. Suspension of trading in the Company's common stock on Nasdaq will be effective at the open of trading on August 8
- SECSEC Form 6-K filed by Centogene N.V.6-K - Centogene N.V. (0001757097) (Filer)
- PRCENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic FactorsInitial data from largest international Parkinson's disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential candidates to be included in gene-targeted trialsThe Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of Parkinson's disease (PD) to establish a better understanding of disease progression, diagnosis, and treatment for patients CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases
- NEWSCentogene shares are trading higher after the company signed a Memorandum of Understanding with C-Path for collaboration in lysosomal disease research and drug development.
- NEWSCentogene And C-Path Sign MOU For Collaboration In Lysosomal Disease Research And Drug Development
- SECSEC Form 6-K filed by Centogene N.V.6-K - Centogene N.V. (0001757097) (Filer)
- PRC-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug DevelopmentTUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Understanding (MOU) to advance drug development for lysosomal diseases (LDs) and improve the quality of life for those impacted by these conditions. The MOU outlines a strategic partnership aimed at leveraging both organizations' strengths in genetic and real-world data (RWD) to overcome barriers in dev
- SECSEC Form 6-K filed by Centogene N.V.6-K - Centogene N.V. (0001757097) (Filer)
- PRCENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General MeetingCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's 2024 Annual General Meeting. Shareholders voted in favor of all proposals. The shareholders extended the period for drawing up the Dutch statutory annual accounts and board report for the financial year ended December 31, 2023. The shareholders also instructed Ernst & Young Accountants LLP as the external auditor of the Company for the financial year ended December 31, 2024. In addition, the shareholders adopted t
- SECSEC Form 6-K filed by Centogene N.V.6-K - Centogene N.V. (0001757097) (Filer)
- SECSEC Form IRANNOTICE filed by Centogene N.V.IRANNOTICE - Centogene N.V. (0001757097) (Filer)
- NEWSCentogene shares are trading higher after the company reported a year-over-year increase in FY23 EPS results.
- NEWSCENTOGENE FY23 EPS €(1.27) Vs €(1.19); Revenue €48.5 Million Up From €47.5 Million YoY;
- PRCENTOGENE Reports Full Year 2023 Financial Results and Recent Business HighlightsReported Full Year 2023 total revenues of 2% growth at €48.5 millionSecured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIFPositioned for strong performance in 2024, driven by new and existing Pharma business and solid Diagnostic growth in line with industry standards; guidance of FY2024 total revenue growth between 10-15%Ongoing strategic alternatives process focused on sustainable long-term value creation for the benefit of its stakeholders CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) ("we" or the "Company"), the essential life scienc
- SECSEC Form 20-F filed by Centogene N.V.20-F - Centogene N.V. (0001757097) (Filer)
- NEWSCENTOGENE Entered Into Agrements With Lifera; Provides ~$20M Funding
- PRCENTOGENE Secures Approx. $20 Million to Strengthen Cash PositionCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has entered into a set of agreements with Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF) in Saudi Arabia. The expanded relationship, which takes the form of a $15 million purchase of certain of CENTOGENE's accounts receivables (AR) and an increased investment in the parties' joint venture (JV) relationship, provides funding in aggregate of approximately $20 million to CENTOGENE to support ongoing activities and to position t
- SECSEC Form 6-K filed by Centogene N.V.6-K - Centogene N.V. (0001757097) (Filer)
- SECSEC Form 6-K filed by Centogene N.V.6-K - Centogene N.V. (0001757097) (Filer)
CNTG FAQ
7 questionsWhat does Centogene N.V. do?
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and...Where does CNTG stock trade?
Centogene N.V. (CNTG) is listed on NASDAQ.What sector and industry is CNTG in?
Centogene N.V. operates in the Health Care sector, Medical Specialities industry.When did Centogene N.V. go public?
Centogene N.V. (CNTG) completed its IPO in 2019.What are analysts saying about CNTG?
Centogene N.V. has had 1 recent analyst action on file. The most recent action was from Credit Suisse: Outperform with a $1400.00 price target on 2021-08-05. Recent price targets cluster around $1400.00.What companies are similar to CNTG?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare CNTG side-by-side with any of them on Quantisnow.How can I track CNTG on Quantisnow?
Quantisnow aggregates Centogene N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CNTG to receive live email and push alerts on every new disclosure.